Glulisine Pre- and Postmeal
Phase 1
Completed
- Conditions
- Diabetes Mellitus Type 1
- Registration Number
- NCT00290043
- Lead Sponsor
- Sanofi
- Brief Summary
To investigate in type 1 diabetic patients the glucodynamic response to HMR1964 insulin and RHI (HOE31HPR100) injected subcutaneously before and after a standard meal
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Type 1 diabetes mellitus
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Outcome measures: Post-prandial glucose and insulin concentrations. Outcome: In T1DM, insulin glulisine provides a better mimic of the physiological postprandial glucose disposal than RHI.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of HMR1964 insulin compared to rapid-acting insulin in type 1 diabetes?
How does premeal versus postmeal administration of HMR1964 affect glycemic control in type 1 diabetic patients?
What biomarkers correlate with improved glucodynamic response to HMR1964 in phase 1 trials for type 1 diabetes?
What adverse events are associated with HMR1964 insulin in type 1 diabetes phase 1 studies?
How does HMR1964 compare to other rapid-acting insulins like aspart or glargine in type 1 diabetes management?